Interleukin 1 Receptor Associated Kinase 4 - Pipeline Review, H2 2019
Interleukin 1 Receptor Associated Kinase 4 - Pipeline Review, H2 2019
SUMMARY
According to the recently published report 'Interleukin 1 Receptor Associated Kinase 4 - Pipeline Review, H2 2019'; Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) pipeline Target constitutes close to 17 molecules.
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Interleukin-1 receptor-associated kinase 4 (IRAK-4) is a protein kinase involved in signaling innate immune responses from Toll-like receptors. Mutations in IRAK-4 result in IRAK4 deficiency and recurrent invasive pneumococcal disease. It phosphorylates E3 ubiquitin ligases Pellino proteins to promote pellino-mediated polyubiquitination of IRAK1. Ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. MAP3K7/TAK1 activates IKKs leading to NF-kappa-B nuclear translocation and activation.
The report 'Interleukin 1 Receptor Associated Kinase 4 - Pipeline Review, H2 2019' outlays comprehensive information on the Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, Stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery Stages are 1, 4, 9 and 3 respectively. Report covers products from therapy areas Immunology, Oncology, Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Infectious Disease and Women's Health which include indications Rheumatoid Arthritis, Diffuse Large B-Cell Lymphoma, Inflammation, Psoriasis, Autoimmune Disorders, Gouty Arthritis (Gout), Arthritis, Endometriosis, Follicular Lymphoma, Lupus Erythematosus, Lymphoma, Multiple Sclerosis, Myelodysplastic Syndrome, Pelvic Inflammatory Disease (Pelvic Infections), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Interleukin 1 Receptor Associated Kinase 4 - Pipeline Review, H2 2019'; Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) pipeline Target constitutes close to 17 molecules.
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Interleukin-1 receptor-associated kinase 4 (IRAK-4) is a protein kinase involved in signaling innate immune responses from Toll-like receptors. Mutations in IRAK-4 result in IRAK4 deficiency and recurrent invasive pneumococcal disease. It phosphorylates E3 ubiquitin ligases Pellino proteins to promote pellino-mediated polyubiquitination of IRAK1. Ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. MAP3K7/TAK1 activates IKKs leading to NF-kappa-B nuclear translocation and activation.
The report 'Interleukin 1 Receptor Associated Kinase 4 - Pipeline Review, H2 2019' outlays comprehensive information on the Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, Stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery Stages are 1, 4, 9 and 3 respectively. Report covers products from therapy areas Immunology, Oncology, Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Infectious Disease and Women's Health which include indications Rheumatoid Arthritis, Diffuse Large B-Cell Lymphoma, Inflammation, Psoriasis, Autoimmune Disorders, Gouty Arthritis (Gout), Arthritis, Endometriosis, Follicular Lymphoma, Lupus Erythematosus, Lymphoma, Multiple Sclerosis, Myelodysplastic Syndrome, Pelvic Inflammatory Disease (Pelvic Infections), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1)
- The report reviews Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Overview
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Amgen Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Bayer AG
Beijing Hanmi Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
Genentech Inc
Kymera Therapeutics LLC
Merck & Co Inc
Nyrada Inc
Pfizer Inc
Rigel Pharmaceuticals Inc
TG Therapeutics Inc
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Drug Profiles
BAY-1830839 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1834845 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CA-4948 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KYM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-2110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-2158 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-346 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06650833 MR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-835 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit BTK and IRAK4 for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit IRAK4 for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IRAK-4 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IRAK4 for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IRAK4 for Autoimmune Disorders, Cardiovascular Disease, Inflammation and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IRAK4 for B-Cell Lymphoma and Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IRAK4 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IRAK4 for Inflammatory Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Dormant Products
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Appendix
Global Markets Direct Report Coverage
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Overview
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Amgen Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Bayer AG
Beijing Hanmi Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
Genentech Inc
Kymera Therapeutics LLC
Merck & Co Inc
Nyrada Inc
Pfizer Inc
Rigel Pharmaceuticals Inc
TG Therapeutics Inc
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Drug Profiles
BAY-1830839 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1834845 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CA-4948 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KYM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-2110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-2158 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-346 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06650833 MR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-835 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit BTK and IRAK4 for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit IRAK4 for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IRAK-4 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IRAK4 for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IRAK4 for Autoimmune Disorders, Cardiovascular Disease, Inflammation and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IRAK4 for B-Cell Lymphoma and Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IRAK4 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IRAK4 for Inflammatory Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Dormant Products
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Appendix
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Amgen Inc, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Aurigene Discovery Technologies Ltd, H2 2019
Pipeline by Bayer AG, H2 2019
Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Genentech Inc, H2 2019
Pipeline by Kymera Therapeutics LLC, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Nyrada Inc, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Rigel Pharmaceuticals Inc, H2 2019
Pipeline by TG Therapeutics Inc, H2 2019
Dormant Projects, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Amgen Inc, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Aurigene Discovery Technologies Ltd, H2 2019
Pipeline by Bayer AG, H2 2019
Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Genentech Inc, H2 2019
Pipeline by Kymera Therapeutics LLC, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Nyrada Inc, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Rigel Pharmaceuticals Inc, H2 2019
Pipeline by TG Therapeutics Inc, H2 2019
Dormant Projects, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
COMPANIES MENTIONED
Amgen Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Bayer AG
Beijing Hanmi Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
Genentech Inc
Kymera Therapeutics LLC
Merck & Co Inc
Nyrada Inc
Pfizer Inc
Rigel Pharmaceuticals Inc
TG Therapeutics Inc
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
COMPANIES MENTIONED
Amgen Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Bayer AG
Beijing Hanmi Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
Genentech Inc
Kymera Therapeutics LLC
Merck & Co Inc
Nyrada Inc
Pfizer Inc
Rigel Pharmaceuticals Inc
TG Therapeutics Inc
